Granted Patent
B2
US 12,389,888 · App. 17/238,710 · Granted Aug 19, 2025
Mice expressing a limited immunoglobulin light chain repertoire
Inventors:
John McWhirter (Sanremo, IT); Lynn Macdonald (Harrison, NY); Sean Stevens (Del Mar, CA); Andrew J. Murphy (Croton-on-Hudson, NY)
Assignee:
Regeneron Pharmaceuticals, Inc.
A01K67/0278A01K67/0275C07K16/00C07K16/462C12N15/8509A01K2207/15A01K2217/072A01K2217/15A01K2227/105A01K2267/01C07K2317/21C07K2317/24C07K2317/515
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that present a choice of two human light chain variable gene segments such that the immunoglobulin light chains expresses by the mouse comprise one of the two human light chain variable gene segments. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided.
Claims (21)
1. A method of making a mouse, comprising genetically modifying the germline genome of the mouse so that it includes:
a) exactly two unrearranged human immunoglobulin Vκ gene segments and five unrearranged human immunoglobulin Jκ gene segments operably linked to a mouse immunoglobulin light chain constant region sequence at the endogenous kappa light chain loci of the mouse, wherein the two unrearranged human immunoglobulin Vκ gene segments are a human Vκ1-39 gene segment and a human Vκ3-20 gene segment; and
b) one or more unrearranged human immunoglobulin V H gene segments, one or more unrearranged human immunoglobulin D H gene segments, and one or more unrearranged human immunoglobulin J H gene segments operably linked to a mouse immunoglobulin heavy chain constant region sequence at the endogenous heavy chain loci of the mouse;
wherein the unrearranged human immunoglobulin heavy chain and kappa light chain gene segments are capable of rearranging and encoding human immunoglobulin variable domains of an antibody, and wherein the mouse does not comprise endogenous immunoglobulin Vκ or Jκ gene segments that are capable of rearranging to form an immunoglobulin light chain variable region sequence.
2. The method of claim 1 , wherein the five unrearranged human immunoglobulin Jκ gene segments are a human Jκ1 gene segment, a human Jκ2 gene segment, a human Jκ3 gene segment, a human Jκ4 gene segment, and a human Jκ5 gene segment.
3. The method of claim 1 , wherein the mouse light chain constant region is a mouse Cκ constant region.
4. The method of claim 1 , wherein the human Vκ1-39 gene segment in the germline genome of the mouse is a human germline Vκ1-39 gene segment and the human Vκ3-20 gene segment in the germline genome of the mouse is a human germline Vκ3-20 gene segment.
5. The method of claim 2 , wherein the germline genome of the mouse comprises in order: the human Vκ1-39 gene segment, the human Vκ3-20 gene segment, the human Jκ1 gene segment, the human Jκ2 gene segment, the human Jκ3 gene segment, the human Jκ4 gene segment, and the human Jκ5 gene segment.
6. The method of claim 1 , wherein the mouse comprises a nonfunctional λ light chain locus.
7. A method for making an antibody that binds to an antigen of interest, wherein the method comprises:
(a) isolating one or more B lymphocytes from a mouse that has been exposed to an antigen of interest, wherein the one or more B lymphocytes express an antibody that binds the antigen of interest, and wherein the mouse comprises:
(i) exactly two unrearranged human immunoglobulin Vκ gene segments and five unrearranged human immunoglobulin Jκ gene segments operably linked to a mouse immunoglobulin light chain constant region sequence at the endogenous kappa light chain loci of the mouse, wherein the two unrearranged human immunoglobulin Vκ gene segments are a human Vκ1-39 gene segment and a human Vκ3-20 gene segment; and
(ii) one or more unrearranged human immunoglobulin V H gene segments, one or more unrearranged human immunoglobulin D H gene segments, and one or more unrearranged human immunoglobulin J H gene segments operably linked to a mouse immunoglobulin heavy chain constant region sequence at the endogenous heavy chain loci of the mouse;
wherein the unrearranged human immunoglobulin heavy chain and kappa light chain gene segments are capable of rearranging and encoding human immunoglobulin variable domains of an antibody, and wherein the mouse does not comprise endogenous immunoglobulin Vκ or Jκ gene segments that are capable of rearranging to form an immunoglobulin light chain variable region sequence;
(b) identifying an amino acid sequence of human variable domain of the antibody that binds the antigen of interest or identifying a nucleotide sequence that encodes human variable domain of the antibody that binds that antigen of interest; and
(c) employing the amino acid sequence or the nucleotide sequence of (b) to make an antibody that binds the antigen of interest.
8. The method of claim 7 , wherein the five unrearranged human immunoglobulin Jκ gene segments are a human Jκ1 gene segment, a human Jκ2 gene segment, a human Jκ3 gene segment, a human Jκ4 gene segment, and a human Jκ5 gene segment.
9. The method of claim 7 , wherein the mouse light chain constant region is a mouse Cκ constant region.
10. The method of claim 7 , wherein the human Vκ1-39 gene segment in the germline genome of the mouse is a human germline Vκ1-39 gene segment and the human Vκ3-20 gene segment in the germline genome of the mouse is a human germline Vκ3-20 gene segment.
11. The method of claim 8 , wherein the germline genome of the mouse comprises in order: the human Vκ1-39 gene segment, the human Vκ3-20 gene segment, the human Jκ1 gene segment, the human Jκ2 gene segment, the human Jκ3 gene segment, the human Jκ4 gene segment, and the human Jκ5 gene segment.
12. The method of claim 7 , wherein the mouse comprises a nonfunctional 2 light chain locus.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 8, 2024
From: MCWHIRTER, JOHN; MACDONALD, LYNN; STEVENS, SEAN; MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 066756/0001 →
Continuity (10)
Provisional Application
61302282
· Feb 8, 2010
References Cited (400)
US 5545807A
· Surani et al.
· 1996
[cited by applicant]
US 5574205A
· Kucherlapati et al.
· 1996
[cited by applicant]
US 5667988A
· Barbas et al.
· 1997
[cited by applicant]
US 5770429A
· Lonberg et al.
· 1998
[cited by applicant]
US 5789208A
· Sharon
· 1998
[cited by applicant]
US 5888789A
· Rodriguez
· 1999
[cited by applicant]
US 5939598A
· Kucherlapati et al.
· 1999
[cited by applicant]
US 6075181A
· Kucherlapati et al.
· 2000
[cited by applicant]
US 6080560A
· Russell et al.
· 2000
[cited by applicant]
US 6096551A
· Barbas et al.
· 2000
[cited by applicant]
US 6114598A
· Kucherlapati et al.
· 2000
[cited by applicant]
US 6139835A
· Kucherlapati et al.
· 2000
[cited by applicant]
US 6150584A
· Kucherlapati et al.
· 2000
[cited by applicant]
US 6162963A
· Kucherlapati et al.
· 2000
[cited by applicant]
US 6514752B1
· Kucherlapati et al.
· 2003
[cited by applicant]
US 6551592B2
· Lindhofer et al.
· 2003
[cited by applicant]
US 6596541B2
· Murphy et al.
· 2003
[cited by applicant]
US 6657103B1
· Kucherlapati et al.
· 2003
[cited by applicant]
US 6673986B1
· Kucherlapati et al.
· 2004
[cited by applicant]
US 6713610B1
· Kucherlapati et al.
· 2004
[cited by applicant]
US 6914128B1
· Salfeld et al.
· 2005
[cited by applicant]
US 6998514B2
· Bruggemann
· 2006
[cited by applicant]
US 7052873B2
· Tsuchiya
· 2006
[cited by applicant]
US 7064244B2
· Jakobovits et al.
· 2006
[cited by applicant]
US 7067284B1
· Barbas et al.
· 2006
[cited by applicant]
US 7084260B1
· Lonberg et al.
· 2006
[cited by applicant]
US 7105348B2
· Murphy et al.
· 2006
[cited by applicant]
US 7119248B1
· Rajewsky et al.
· 2006
[cited by applicant]
US 7129084B2
· Buelow et al.
· 2006
[cited by applicant]
US 7183076B2
· Arathoon et al.
· 2007
[cited by applicant]
US 7262028B2
· Van Berkel et al.
· 2007
[cited by applicant]
US 7435871B2
· Green et al.
· 2008
[cited by applicant]
US 7501552B2
· Lonberg et al.
· 2009
[cited by applicant]
US 7534604B2
· Fandl et al.
· 2009
[cited by applicant]
US 7585668B2
· Buelow et al.
· 2009
[cited by applicant]
US 7605237B2
· Stevens et al.
· 2009
[cited by applicant]
US 7642228B2
· Carter et al.
· 2010
[cited by applicant]
US 7704498B2
· Gerritsen et al.
· 2010
[cited by applicant]
US 7879985B2
· Urso et al.
· 2011
[cited by applicant]
US 7910798B2
· Tanamachi et al.
· 2011
[cited by applicant]
US 8158419B2
· Lonberg et al.
· 2012
[cited by applicant]
US 8502018B2
· Murphy et al.
· 2013
[cited by applicant]
US 8592562B2
· Kannan et al.
· 2013
[cited by applicant]
US 8642835B2
· MacDonald et al.
· 2014
[cited by applicant]
US 9248182B2
· De Kruif et al.
· 2016
[cited by applicant]
US 9796788B2
· McWhirter
· 2017
[cited by examiner]
US 20030108925A1
· Dix et al.
· 2003
[cited by applicant]
US 20030138440A1
· Fang et al.
· 2003
[cited by applicant]
US 20040018626A1
· Murphy et al.
· 2004
[cited by applicant]
US 20040052773A1
· Bogen et al.
· 2004
[cited by applicant]
US 20040146991A1
· Tsuji et al.
· 2004
[cited by applicant]
US 20050153392A1
· Buelow et al.
· 2005
[cited by applicant]
US 20050229263A1
· Buelow
· 2005
[cited by applicant]
US 20060015949A1
· Lonberg et al.
· 2006
[cited by applicant]
US 20060083747A1
· Winter et al.
· 2006
[cited by applicant]
US 20060117398A1
· Buelow et al.
· 2006
[cited by applicant]
US 20060153826A1
· Arnould et al.
· 2006
[cited by applicant]
US 20060199204A1
· Dix et al.
· 2006
[cited by applicant]
US 20070009957A1
· Bowdish et al.
· 2007
[cited by applicant]
US 20090083879A1
· Dhugga
· 2009
[cited by applicant]
US 20100069614A1
· Houtzager et al.
· 2010
[cited by applicant]
US 20120021409A1
· McWhirter et al.
· 2012
[cited by applicant]
US 20120192300A1
· Babb et al.
· 2012
[cited by applicant]
US 20120204278A1
· Bradley et al.
· 2012
[cited by applicant]
US 20130045492A1
· Babb et al.
· 2013
[cited by applicant]
US 20240156070A1
· Babb et al.
· 2024
[cited by applicant]
CN 1277632A
· 2000
[cited by applicant]
CN 1484707A
· 2004
[cited by applicant]
CN 1560081A
· 2005
[cited by applicant]
CN 101962408A
· 2011
[cited by applicant]
EP 0364096A2
· 1990
[cited by applicant]
EP 1298207A1
· 2003
[cited by applicant]
EP 1439234A1
· 2004
[cited by applicant]
EP 1605058A1
· 2005
[cited by applicant]
EP 1505148B1
· 2009
[cited by applicant]
EP 2147594A1
· 2010
[cited by applicant]
EP 2501817A1
· 2012
[cited by applicant]
EP 2505654A1
· 2012
[cited by applicant]
EP 2517556A2
· 2012
[cited by applicant]
EP 2517557A2
· 2012
[cited by applicant]
EP 2556747A2
· 2013
[cited by applicant]
EP 2564695A1
· 2013
[cited by applicant]
EP 2582230A1
· 2013
[cited by applicant]
RU 2434882C2
· 2011
[cited by applicant]
WO WO9004036A1
· 1990
[cited by applicant]
WO WO9100906A1
· 1991
[cited by applicant]
WO WO9108216A1
· 1991
[cited by applicant]
WO WO9203918A1
· 1992
[cited by applicant]
WO WO9402602A1
· 1994
[cited by applicant]
WO WO9404690A1
· 1994
[cited by applicant]
WO WO9425585A1
· 1994
[cited by applicant]
WO WO9517085A1
· 1995
[cited by applicant]
WO WO9517500A1
· 1995
[cited by applicant]
WO WO9713852A1
· 1997
[cited by applicant]
WO WO9742313A1
· 1997
[cited by applicant]
WO WO9824893A2
· 1998
[cited by applicant]
WO WO9839416A1
· 1998
[cited by applicant]
WO WO9846645A2
· 1998
[cited by applicant]
WO WO199850431A2
· 1998
[cited by applicant]
WO WO1999018212A1
· 1999
[cited by applicant]
WO WO9945962A1
· 1999
[cited by applicant]
WO WO0063403A2
· 2000
[cited by applicant]
WO WO0164929A1
· 2001
[cited by applicant]
WO WO0208409A2
· 2002
[cited by applicant]
WO WO0212437A2
· 2002
[cited by applicant]
WO WO0218948A2
· 2002
[cited by applicant]
WO WO2002036789A2
· 2002
[cited by applicant]
WO WO02053596A2
· 2002
[cited by applicant]
WO WO02066630
· 2002
[cited by examiner]
WO WO02066630A1
· 2002
[cited by applicant]
WO WO02085944A2
· 2002
[cited by applicant]
WO WO02085945A2
· 2002
[cited by applicant]
WO WO03002609A2
· 2003
[cited by applicant]
WO WO03052416A2
· 2003
[cited by applicant]
WO WO03061363A2
· 2003
[cited by applicant]
WO WO03106495A2
· 2003
[cited by applicant]
WO WO2004006955A1
· 2004
[cited by applicant]
WO WO2004009618A2
· 2004
[cited by applicant]
WO WO2004049794A2
· 2004
[cited by applicant]
WO WO2004050838A2
· 2004
[cited by applicant]
WO WO2004058820A2
· 2004
[cited by applicant]
WO WO2004106375A1
· 2004
[cited by applicant]
WO WO2005007696A2
· 2005
[cited by applicant]
WO WO2005019463A1
· 2005
[cited by applicant]
WO WO2005038001A2
· 2005
[cited by applicant]
WO WO2006117699A2
· 2006
[cited by applicant]
WO WO2006122442A1
· 2006
[cited by applicant]
WO WO2007096779A2
· 2007
[cited by applicant]
WO WO2007117410A2
· 2007
[cited by applicant]
WO WO2008022391A1
· 2008
[cited by applicant]
WO WO2008054606A2
· 2008
[cited by applicant]
WO WO2008076379A2
· 2008
[cited by applicant]
WO WO2008081197A1
· 2008
[cited by applicant]
WO WO2008112922A2
· 2008
[cited by applicant]
WO WO2008151081A1
· 2008
[cited by applicant]
WO WO2009013620A2
· 2009
[cited by applicant]
WO WO2009051974A1
· 2009
[cited by applicant]
WO WO2009089004A1
· 2009
[cited by applicant]
WO WO2009097006A2
· 2009
[cited by applicant]
WO WO2009129247A2
· 2009
[cited by applicant]
WO WO2009143472A2
· 2009
[cited by applicant]
WO WO2009157771A2
· 2009
[cited by applicant]
WO WO2010039900A2
· 2010
[cited by applicant]
WO WO2010053751A1
· 2010
[cited by applicant]
WO WO2010054007A1
· 2010
[cited by applicant]
WO WO2010070263A1
· 2010
[cited by applicant]
WO WO2010097385A1
· 2010
[cited by applicant]
WO WO2010136598A1
· 2010
[cited by applicant]
WO WO2010151792A1
· 2010
[cited by applicant]
WO WO2011004192A1
· 2011
[cited by applicant]
WO WO2011062207A1
· 2011
[cited by applicant]
WO WO2011072204A1
· 2011
[cited by applicant]
WO WO2011097603A1
· 2011
[cited by applicant]
WO WO2011143545A1
· 2011
[cited by applicant]
WO WO2011158009A1
· 2011
[cited by applicant]
WO WO2011163311A1
· 2011
[cited by applicant]
WO WO2011163314A1
· 2011
[cited by applicant]
WO WO2012018764A1
· 2012
[cited by applicant]
WO WO2012141798A1
· 2012
[cited by applicant]
WO WO2012148873A2
· 2012
[cited by applicant]
WO WO2013022782A1
· 2013
[cited by applicant]
WO WO2013059230A1
· 2013
[cited by applicant]
WO WO2013079953A1
· 2013
[cited by applicant]
WO WO2013134263A1
· 2013
[cited by applicant]
WO WO2013184761A1
· 2013
[cited by applicant]
WO WO2014160179A1
· 2014
[cited by applicant]
WO WO2014160202A1
· 2014
[cited by applicant]
De Wildt et al. (1999) J. Mol. Biol., vol. 285, 895-901.
[cited by examiner]
Merchant et al. (1998) Nat. Biotech., vol. 16, 677-681.
[cited by examiner]
Adderson, E. et al., Restricted immunoglobulin VH usage and VDJ combinations in the human response to Haemophilus influenzae type b capsular polysaccharide. Nucleotide sequences of monospecific anti-Haemophilus antibodi…
[cited by applicant]
Al-Lazikani, B. et al., Standard conformations for the canonical structures of immunoglobulins, J. Mol. Biol., 273(4):927-48 (1997).
[cited by applicant]
Applicant's Written Submissions for AU2009263082, 49 pages (Sep. 6, 2016).
[cited by applicant]
Arnaout, R. et al., High-resolution description of antibody heavy-chain repertoires in; humans PLoS One, 6(8):e22365 (2011).
[cited by applicant]
Arnold, L. et al., Development of B-1 cells: segregation of phosphatidyl choline-specific B cells to the B-1 population occurs after immunoglobulin gene expression, J. Exp. Med., 179:1585-1595 (1994).
[cited by applicant]
Askew, G.R. et al., Site-directed point mutations in embryonic stem cells: a gene-targeting tag-and-exchange strategy, Mol. Cell Biol., 13(7):4115-24 (1993).
[cited by applicant]
Aucouturier, P.et al., Monoclonal Ig L chain and L chain V domain fragment crystallization in myeloma-associated Fanconi's syndrome, J. Immunol., 150( 8):3561-3568 (1993).
[cited by applicant]
Author Not Known, Additional post-filing data and letter filed by the Applicant/Patentee for corresponding European application 09075279.1, now opposed patent EP 2147594 B1, 4 pages (Jun. 13 2013).
[cited by applicant]
Author Not Known, Chapter 6: The Development of B Lymphocytes, Immuno Biology: The Immune System in Health and Disease, 4th Edition, Janeway et al. ed., pp. 195-208 (1999).
[cited by applicant]
Author Not Known, Chapter 8: The Development and Survival of Lymphocytes, Janeway's Immunobiology, 8th Edition, Eds. Kenneth Murphy et al, Garland Science (ISBN: 9780815342434), whole document, in particular p. 279 and …
[cited by applicant]
Author Not Known, Mouse strain, document #3 submitted with Third Party Observation, filed in GB2012052956, 4 pages (Mar. 26, 2014).
[cited by applicant]
Author Not Known, Next generation transgenic mice for therapeutic human antibodies, Description of MeMoTM, filed by the Applicant/Patentee in prosecution for corresponding European application 09075279.1, now opposed pa…
[cited by applicant]
Author Not Known, V-BASE Sequence Directory, 6 pages, retrieved on Jun. 6, 2016 <http://www2.mrc-lmb.cam.ac.uk/vbase/list2.php.
[cited by applicant]
Baeuerle, P.A. and Reinhardt, C., Bispecific T-cell engaging antibodies for cancer; therapy, Cancer Res., 69(12):4941-4 (2009).
[cited by applicant]
Bauer, S. et al., Structure and pre-B lymphocyte restricted expression of the VpreB gene in humans and conservation of its structure in other mammalian species, The EMBO Journal, 7(1):111-116 (1988).
[cited by applicant]
Billiard, F. et al., Ongoing DII4-Notch signaling is required for T-cell homeostasis in the adult thymus, Eur. J. Immunol., 41(8):2207-16 (2011).
[cited by applicant]
Blaas, L. et al., Bacterial artificial chromosomes improve recombinant protein production in mammalian cells, BMC Biotechnol., 9:3 (2009).
[cited by applicant]
Bode, J. et al., The transgeneticist's toolbox: novel methods for the targeted modification of eukaryotic genomes, Biol. Chem., 381(9-10):801-13 (2000).
[cited by applicant]
Bot, A. et al., V2-Light Chain Genes Reconstitute Immune Responses to Defined Carbohydrate Antigens or Haptens by Utilizing Different VH Genes, Molecular Immunology, 33(17/18):1359-1368 (1996).
[cited by applicant]
Brezinschek, H. et al., Pairing of variable heavy and variable kappa chains in individual naïve and memory B cells, J. Immunol., 160(10):4762-4767 (1998).
[cited by applicant]
Brezinschek, H.P. et al., Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(−)/IgM+ B; Cells, J. Clin. Invest., 99(10):2488-501…
[cited by applicant]
Brief comments on third party observations, EP 11703799.1-1410, submitted to EPO by David Power, 3 pages (Apr. 20, 2015).
[cited by applicant]
Brüggemann, M. and Neuberger, M.S., Strategies for expressing human antibody repertoires in transgenic mice, Immunol. Today, 17(8):391-7 (1996).
[cited by applicant]
Bruggemann, M. et al., A repertoire of monoclonal antibodies with human heavy chains from transgenic mice, Proceedings of the National of Academy of Science USA, 86:6709-6713 (1989).
[cited by applicant]
Bruggemann, M., Human Antibody Expression in Transgenic Mice, Archivum Immunologiae et Therapiae Experimentalis, 49:203-208 (2001).
[cited by applicant]
Brüggemann, M., Human Monoclonal Antibodies from Translocus Mice, Molecular Biology of B Cells, Eds. Honjo, T. and Neuberger, M.S., New York, NY: Academic Press, pp. 547-561 (2004).
[cited by applicant]
Campbell, K.H. et al., Sheep cloned by nuclear transfer from a cultured cell line, Nature, 380(6569):64-6 (1996).
[cited by applicant]
Carmack, C. et al., Influence of a V kappa 8 L chain transgene on endogenous rearrangements and the immune response to the HA(Sb) determinant of influenza virus, J. Immunol., 147(6):2024-2033 (1991).
[cited by applicant]
Carter, P., Bispecific human IgG by design, Journal of Immunological Methods, 248(1-2):7-15 (2001).
[cited by applicant]
Cascalho, M. et al., A quasi-monoclonal mouse, Science, 272(5268):1649-1652 (1996).
[cited by applicant]
Casellas, R. et al., Contribution of receptor editing to the antibody repertoire, Science, 291(5508):1541-4 (2001).
[cited by applicant]
Chen, C. et al., Deletion and Editing of B Cells that Express Antibodies to DNA, Journal of Immunology, 152(4):1970-1982 (1994).
[cited by applicant]
Choi, I. et al., Characterization and comparative genomic analysis of intronless Adams with testicular gene expression, Genomics, 83(4):636-46 (2004).
[cited by applicant]
Chothia, C. and Lesk, A.M., Canonical structures for the hypervariable regions of; Immunoglobulins, J. Mol. Biol., 196(4):901-17 (1987).
[cited by applicant]
Choulika, A. et al., Induction of homologous recombination in mammalian chromosomes by using the I-Scel system of
[cited by applicant]
Cohen-Tannoudji, M. et al., I-Scel-induced gene replacement at a natural locus in; embryonic stem cells, Mol. Cell. Biol., 18(3):1444-8 (1998).
[cited by applicant]
Collins, A. et al., The reported germline repertoire of human immunoglobulin kappa chain genes is relatively complete and accurate, Immunogenetics, 60:669-676 (2008).
[cited by applicant]
Combriato, G. and Klobeck, H.G., Regulation of human Ig lambda light chain gene expression by NF-kappa B, J. Immunol., 168(3):1259-66 (2002).
[cited by applicant]
Conrath, K. et al., Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs, J. Biol. Chem., 276(10):7346-50 (2001).
[cited by applicant]
Corcos, D. et al., Pre-B-cell development in the absence of lambda 5 in transgenic mice expressing a heavy-chain disease protein, Curr. Biol., 5(10):1140-8 (1995).
[cited by applicant]
Corrected Claims in JP5749161 (English and Japanese), 6 pages.
[cited by applicant]
Cover Letter—Applicant Post-Hearing Submissions in AU2009263082, 1 page (Oct. 19, 2016).
[cited by applicant]
Cowen, N.J. et al., Purification and Sequence Analysis of the mRNA Coding for an Immunoglobulin Heavy Chain, European J. of Biochem., 61(2): 355-368 (1976).
[cited by applicant]
Davies, N. et al., Creation of Mice Expressing Human Antibody Light Chains by Introduction of a Yeast Artificial Chromosome Containing the Core Region of the Human Immunoglobulin κ Locus, Nature Biotechnology 11:911-914…
[cited by applicant]
De Kruif, J. et al., Human Immunoglobulin Repertoires against Tetanus Toxoid Contain a Large and Diverse Fraction of High-Affinity Promiscuous VH Genes, Journal of Molecular Biology, 387:548-558 (2009).
[cited by applicant]
De Kruif, J. et al., Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library, Proc. Natl. Acad. Sci. U S A, 92(9):3938-42 (1995).
[cited by applicant]
De Wildt, R. et al., Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire, J. Mol. Biol., 285(3):895-901 (1999).
[cited by applicant]
Dechiara, T.M. et al., Chapter 16: VelociMouse: Fully ES Cell-Derived FO Generation Mice Obtained from the Injection of ES Cells into 8-Cell Stage Embryos, Gene Knockout Protocols: Second Edition, vol. 530, Humana Press…
[cited by applicant]
Declaration Appendix as filed in U.S. Appl. No. 13/798,310, on Jul. 18, 2014 (7 pages).
[cited by applicant]
Declaration of Andrew M. Scharenberg, M.D., filed in prosecution of U.S. Appl. No. 12/130,818, 21 pages, signed Oct. 4, 2010.
[cited by applicant]
Declaration of Brink dated Apr. 30, 2015, as filed in AU Application No. 2009263082, 34 pages.
[cited by applicant]
Declaration of Brink dated Jun. 2, 2015, as filed in AU Application No. 2009263082, 38 pages.
[cited by applicant]
Declaration of Brink dated Sep. 27, 2016, as filed against EP Patent No. 2,147,594 B1 (European patent application No. 09075279.1), 33 pages.
[cited by applicant]
Declaration of DeFranco dated Dec. 21, 2014, as filed in AU Application No. 2009263082, 56 pages.
[cited by applicant]
Declaration of DeFranco dated Oct. 19, 2015, as filed in AU Application No. 2009263082, 31 pages.
[cited by applicant]
Declaration of Denley dated May 1, 2015, as filed in AU Application No. 2009263082, 493 pages.
[cited by applicant]
Declaration of Dr. Joel Martin, Opposition filed against European Patent No. EP 2314629 B1, 13 pages (May 18, 2016).
[cited by applicant]
Declaration of Dr. Ton Logtenberg filed in U.S. Appl. No. 13/750,753, 10 pages (Dec. 18, 2015).
[cited by applicant]
Declaration of Dr. Ton Logtenberg filed in U.S. Appl. No. 13/750,753, 4 pages (Sep. 15, 2015).
[cited by applicant]
Declaration of Goodnow dated Oct. 19, 2015, as filed in AU Application No. 2009263082, 81 pages.
[cited by applicant]
Declaration of Hudson dated Jun. 2, 2015, as filed in AU Application No. 2009263082, 81 pages.
[cited by applicant]
Declaration of Hudson dated May 1, 2015, as filed in AU Application No. 2009263082, 52 pages.
[cited by applicant]
Declaration of Lynn E. Macdonald, including Annexes 1-4, as together made publicly available at least upon submission to and online publication by the European Patent Office on Mar. 12, 2015, 13 pages, signed Mar. 3, 20…
[cited by applicant]
Declaration of Murphy dated Dec. 19, 2014, as filed in AU Application No. 2009263082, 18 pages.
[cited by applicant]
Declaration of Professor Ton Logtenberg for EP2314629, 7 pages (May 4, 2016).
[cited by applicant]
Declaration of Robert Brink in AU 2009263082, 19 pages (Oct. 19, 2016).
[cited by applicant]
Declaration of Tarlinton dated Dec. 21, 2014, as filed in AU Application No. 2009263082, 40 pages.
[cited by applicant]
Declaration of Tarlinton dated Oct. 19, 2015, as filed in AU Application No. 2009263082, 24 pages.
[cited by applicant]
Declaration under 37 CFR 1.131 as filed in U.S. Appl. No. 13/798,310 on Jul. 18, 2014 (21 Pages).
[cited by applicant]
Deisenhofer, J., Crystallographic Refinement and Atomic Models of a Human Fc Fragment and Its Complex with Fragment B of Protein A from
[cited by applicant]
Desmyter, A. et al., Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme, Nat. Struct. Biol., 3(9):803-11 (1996).
[cited by applicant]
Dinnyés, A. et al., Somatic cell nuclear transfer: recent progress and challenges, Cloning Stem Cells, 4(1):81-90 (2002).
[cited by applicant]
Donoho, G. et al., Analysis of gene targeting and intrachromosomal homologous recombination stimulated by genomic double-strand breaks in mouse embryonic stem cells, Mol. Cell. Biol., 18(7):4070-8 (1998).
[cited by applicant]
Donohoe, M. et al., Transgenic Human Lambda5 Rescues the Murine Lambda5 Nullizygous Phenotype, Journal of Immunology, 164:5269-5276 (2000).
[cited by applicant]
Echelard, Y., Year of the ox, Nat. Biotechnol., 27(2):146-7 (2009).
[cited by applicant]
Edwards D.R. et al., The ADAM metalloproteinases, Molecular Aspects of Medicine, 29(5):258-89 (2008).
[cited by applicant]
Engel, P. et al., Abnormal B Lymphocyte Development, Activation, and Differentiation in Mice that Lack or Overexpress the CD19 Signal Transduction Molecule, Immunity, 3:39-50 (1995).
[cited by applicant]
English Translation of Arguments dated Jan. 14, 2014, as filed in Merus Japanese Patent No. 5749161, 6 pages.
[cited by applicant]
English Translation of Arguments dated Jan. 5, 2015, as filed in Merus Japanese Patent No. 5749161, 9 pages.
[cited by applicant]
Epinat, J.C., et al. A novel engineered meganuclease induces homologous recombination in yeast and mammalian cells, Nucleic Acids Res., 31(11):2952-62 (2003).
[cited by applicant]
Ewert, S. et al., Biophysical properties of human antibody variable domains, J. Mol. Biol., 325(3):531-53 (2003).
[cited by applicant]
Exhibit A as filed in U.S. Appl. No. 13/798,310 on Jul. 18, 2014 (2 pages).
[cited by applicant]
Exhibit B as filed in U.S. Appl. No. 13/798,310 on Jul. 18, 2014 (2 pages).
[cited by applicant]
Exhibit C as filed in U.S. Appl. No. 13/798,310 on Jul. 18, 2014 (1 page).
[cited by applicant]
Exhibit D as filed in U.S. Appl. No. 13/798,310 on Jul. 18, 2014 (1 page).
[cited by applicant]
Exhibit E as filed in U.S. Appl. No. 13/798,310 on Jul. 18, 2014 (3 pages).
[cited by applicant]
Extended European Search Report for 12 173 456.0, 9 pages (Aug. 21, 2012).
[cited by applicant]
Extended European Search Report for EP 15186515.1, 8 pages (Feb. 3, 2016).
[cited by applicant]
Farner, N.L. et al., Molecular mechanisms and selection influence the generation of the human V lambda J lambda repertoire, J. Immunol., 162(4):2137-45 (1999).
[cited by applicant]
Featherstone, K. et al., The mouse immunoglobulin heavy chain V-D intergenic sequence contains insulators that may regulate ordered V(D)J recombination, J. Biol. Chem. 285(13):9327-9338 (2010).
[cited by applicant]
Fell, H.P. et al., Homologous recombination in hybridoma cells: heavy chain chimeric antibody produced by gene targeting, Proc. Natl. Acad. Sci. U S A., 86(21):8507-11 (1989).
[cited by applicant]
Final Post-Hearing Submission—DeFranco Declaration Annexure in AU2009263082, 10 pages (Oct. 18, 2016).
[cited by applicant]
Final Post-Hearing Submission—Opponent in AU2009263082, 4 pages (Oct. 19, 2016).
[cited by applicant]
Final Response to Opposition in EP2501817, 27 pages (Dec. 23, 2016).
[cited by applicant]
Final Written Submissions for Oral Proceedings Scheduled for Jun. 22, 2016, Opposition to Merus B.V.'s EP 2314629 B1, 13 pages (May 20, 2016).
[cited by applicant]
Final Written Submissions Oral Proceedings Scheduled for Oct. 28, 2016 in EP2147594, 40 pages.
[cited by applicant]
Fischer, N. and Léger, O., Bispecific antibodies: molecules that enable novel therapeutic strategies, Pathobiology, 74(1):3-14 (2007).
[cited by applicant]
Fishwild, D. et al., High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice, Nature Biotechnology, 14:845-851 (1996).
[cited by applicant]
Flavell, D.J., et al., Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin, Br. J…
[cited by applicant]
Forrest, K. B., Opinion of the United States District Court,
[cited by applicant]
Fraenkel, S. et al., Allelic ‘choice’ governs somatic hypermutation in vivo at the immunoglobulin kappa-chain locus, Nat. Immunol., 8(7):715-722 (2007).
[cited by applicant]
Fussenegger, M. et al., Genetic optimization of recombinant glycoprotein production by mammalian cells, Tibtech, 17:35-42 (1999).
[cited by applicant]
Gallo, M.L. et al., The human immunoglobulin loci introduced into mice: V (D) and J gene segment usage similar to that of adult humans, Eur. J. Immunol., 30(2):534-40 (2000).
[cited by applicant]
Gay, D. et al., Receptor editing: an approach by autoreactive B cells to escape tolerance, J. Exp. Med., 177(4):999-1008 (1993).
[cited by applicant]
GenBank Accession No. X97051, GI:564822, first referenced Jan. 9, 1997, updated Nov. 14, 2006 (29 pages).
[cited by applicant]
GenBank Accession No. ABA26122, immunoglobulin light chain variable region, partial [
[cited by applicant]
GenBank Accession No. M87478, Human rearranged IgK mRNA VJC region, Aucouturier et al., 1 page, first referenced Mar. 3, 1992, first seen at NCBI Apr. 27, 1993.
[cited by applicant]
Giallourakis, C.C. et al., Elements between the IgH variable (V) and diversity (D) clusters influence antisense transcription and lineage-specific V(D)K recombination, PNAS, 107(51):22207-22212 (2010).
[cited by applicant]
Giddings, G. et al., Transgenic plants as factories for biopharmaceuticals, Nat. Biotechnol., 18(11):1151-5 (2000).
[cited by applicant]
Goletz, S. et al., Selection of Large Diversities of Antiidiotypic Antibody Fragments by Phage Display, J. Mol. Biol. 315:1087-97, (2002).
[cited by applicant]
Gonzalez-Fernandez, A. and Milstein, C., Analysis of somatic hypermutation in mouse Peyer's patches using immunoglobulin kappa light-chain transgenes, PNAS USA, 90:9862-9866 (1993).
[cited by applicant]
Goodhardt et al., Rearrangement and Expression of rabbit immunoglobulin K light chain gene in transgenic mice; Jun. 1987; PNAS, 84: 4229-4233.
[cited by applicant]
Goyenechea, B. and Milstein, C., Modifying the sequence of an immunoglobulin V-gene alters the resulting pattern of hypermutation, PNAS USA, 93:13979-13984 (1996).
[cited by applicant]
Goyenechea, B. et al., Cells strongly expressing Ig(kappa) transgenes show clonal recruitment of hypermutation: a role for both MAR and the enhancers, EMBO J., 16(13):3987-94 (1997).
[cited by applicant]
Green, L. and Jakobovits, A., Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes, J. Exp. Med., 188(3):483-495 (1998).
[cited by applicant]
Green, L. et al., Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs, Nature Genetics, 7(1):13-21 (1994).
[cited by applicant]
Hagiwara, S., Transgenic expression of VpreB-3 under the control of the immunoglobulin heavy chain enhancer and SV40 promoter, Kobe J. Med. Sci., 42(1):43-59 (1996).
[cited by applicant]
Han, C. et al., Comprehensive analysis of reproductive ADAMs: relationship of ADAM4 and ADAM6; with an ADAM complex required for fertilization in mice, Biology of Reproduction, 80(5):1001-8 (2009).
[cited by applicant]
Harding, F.A. and Lonberg, N., Class switching in human immunoglobulin transgenic Mice, Ann. N Y Acad. Sci., 764:536-46 (1995).
[cited by applicant]
Hardy, R.R. and Hayakawa, K., B cell development pathways, Annu. Rev. Immunol., 19:595-621 (2001).
[cited by applicant]
Hartley, S. and Goodnow, C., Censoring of self-reactive B cells with a range of receptor affinities in transgenic mice expressing heavy chains for a lysozyme-specific antibody, International Immunology, 6:1417-1425 (199…
[cited by applicant]
Hendricks J. et al., Organization of the variable region of the immunoglobulin heavy-chain gene locus of the rat, Immunogenetics, 62(7):479-86 (2010).
[cited by applicant]
Hengstschlager, M. et al., A lambda1 transgene under the control of a heavy chain promoter and enhancer does not undergo somatic hypermutation, Eur. J. Immunol., 24:1649-1656 (1994).
[cited by applicant]
Hiatt, A. et al. Production of antibodies in transgenic plants, Nature, 342(6245):76-8 (1989).
[cited by applicant]
Hochedlinger, K. and R. Jaenisch, Monoclonal Mice Generated by Nuclear Transfer from Mature B and T Donor Cells, Nature, 415(6875):1035-1038, (2002).
[cited by applicant]
Hömig-Hölzel, C. et al., Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis, J. Exp. Med., 205(6):1317-29 (2008).
[cited by applicant]
Houdebine, L.M. Transgenic Animals: Generation and Use. Amsterdam: Harwood Academic Publishers. pp. 397-403 (1997).
[cited by applicant]
Huls, G. et al., Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies, Cancer Res., 59(22):5778-84 (1999).
[cited by applicant]
IMGT V-Quest Analysis of Sequence of GenBank M87478, 7 pages.
[cited by applicant]
Initial Determination in EP Application No. 10186063.3, 11 pages (Nov. 19, 2015).
[cited by applicant]
Initial Post-Hearing Submissions—DeFranco Declaration Annexure for Australian patent application No. 2009263082, 41 pages (Oct. 4, 2016).
[cited by applicant]
Initial Post-Hearing Submissions—Goodnow Declaration Annexure for Australian patent application No. 2009263082, 13 pages (Oct. 4, 2016).
[cited by applicant]
Initial Post-Hearing Submissions (Applicant) Brink Declaration Annex for Australian patent application No. 2009263082, 36 pages (Oct. 4, 2016).
[cited by applicant]
Initial Post-Hearing Submissions (Applicant) for Australian patent application No. 2009263082, 5 pages (Oct. 5, 2016).
[cited by applicant]
Initial Post-Hearing Submissions (Opponent's Initial Supplementary Submissions) for Australian patent application No. 2009263082, 7 pages (Oct. 5, 2016).
[cited by applicant]
Inlay, M. et al., Essential roles of the kappa light chain intronic enhancer and 3′ enhancer in kappa rearrangement and demethylation, Nat. Immunol., 3(5):463-8 (2002).
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2013/044257 mailed Sep. 4, 2013.
[cited by applicant]
International Search Report for PCT/US2011/023971, 5 pages (Apr. 11, 2011).
[cited by applicant]
International Search Report for PCT/US2012/034737, 7 pages (Dec. 6, 2012).
[cited by applicant]
International Search Report for PCT/US2012/049600 (7 pages), mailed Nov. 23, 2012.
[cited by applicant]
International Search Report for PCT/US2013/029125, 6 pages (Jun. 20, 2013).
[cited by applicant]
International Search Report for PCT/US2013/044257, 4 pages (Sep. 4, 2013).
[cited by applicant]
International Search Report for PCT/US2014/025982 dated Jul. 22, 2014 (6 pages).
[cited by applicant]
International Search Report for PCT/US2014/026040 dated Jul. 29, 2014 (5 pages).
[cited by applicant]
Irving, R.A. et al., Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics, J. Immunol. Methods, 248(1-2):31-45 (2001).
[cited by applicant]
Jakobovits, A. et al., From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice, Nature Biotechnology, 25(10):1134-1143 (2007).
[cited by applicant]
Jakobovits, A., Production of fully human antibodies by transgenic mice, Curr. Opin. Biotechnol., 6(5):561-6 (1995).
[cited by applicant]
Jakobovits, Therapeutic Antibodies from XenoMouse Transgenic Mice, Recombinant Antibodies for Immunotherapy, Ed. Little, M., New York, NY: Cambridge University Press, Chapter 7, pp. 89-99 (2009).
[cited by applicant]
Janeway's Immunobiology, Seventh Edition, Murphy, Travers and Walpot, eds., Garland Science, New York and London, Ch. 4, pp. 145-155, and Ch. 7, pp. 266-267 (2008).
[cited by applicant]
Jendreyko, N. et al., Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors, J. Biol. Chem., 278(48):47812-47819 (2003).
[cited by applicant]
Jolly, C. et al., Rapid methods for the analysis of immunoglobulin gene hypermutation: application to transgenic and gene targeted mice, Nucleic Acids Research, 25(10):1913-1919 (1997).
[cited by applicant]
Jones, D. et al., High-level expression of recombinant IgG in the human cell line per.c6, Biotechnol. Prog., 19(1):163-8 (2003).
[cited by applicant]
Joyner, A.L. ed., Gene Targeting: A Practical Approach, Second Edition, Oxford University Press, entire book, 193 pages (2000).
[cited by applicant]
JP Opposition Decision in JP5749161 (English and Japanese), 54 pages (Sep. 7, 2016).
[cited by applicant]
Kabat, E.A., and Wu, T.T., Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determinin…
[cited by applicant]
Kasprzyk, P.G. et al., Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies, Cancer Res., 52(10):2771-6 (1992).
[cited by applicant]
Kaushik et al, “Stochastic pairing of heavy-chain and K light-chain variable gene families occurs in polyclonally activated B cells,” Proc. Natl. Acad. Sci. USA, vol. 87: 4932-4936 (1990).
[cited by applicant]
Klohn, P.C. et al., IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: Dec. 3-6, 2012, San Diego, CA, Mabs, 5(2):178-…
[cited by applicant]
Klotz, E. et al., Somatic hypermutation of a lambda2 transgene under the control of the lambda enhancer or the heavy chain intron enhancer, J. Immunol., 157:4458-4463 (1996).
[cited by applicant]
Klotz, E. et al., Somatic hypermutation of an artificial test substrate within an Ig kappa transgene, J. Immunol., 161:782-790 (1998).
[cited by applicant]
Knappik, A. et al., Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides, J. Mol. Biol., 296(1):57-86 (2000).
[cited by applicant]
Kong, Q. et al., A lambda 3′ enhancer drives active and untemplated somatic hypermutation of a lambda1 transgene, J. Immunol., 161:294-301 (1998).
[cited by applicant]
Kontermann, R.E., Dual targeting strategies with bispecific antibodies, MAbs., 4(2):182-97 (2012).
[cited by applicant]
Kroesen, B.J. et al., Bispecific antibodies for treatment of cancer in experimental animal models and man, Adv. Drug Deliv. Rev., 31(1-2):105-129 (1998).
[cited by applicant]
Kuroiwa, Y. et al., Cloned transchromosomic calves producing human immunoglobulin, Nat. Biotechnol., 20(9):889-94 (2002).
[cited by applicant]
Lam, K. et al., In Vivo Ablation of Surface Immunoglobulin on Mature B Cells by Inducible Gene Targeting Results in Rapid Cell Death, Cell, 90:1073-1083 (1997).
[cited by applicant]
Lantto, J. et al., Capturing the natural diversity of the human antibody response against vaccinia virus, J Virol, 85(4):1820-33 (2011).
[cited by applicant]
Larrick, J.W. and Thomas, D.W., Producing proteins in transgenic plants and animals, Curr. Opin. Biotechnol., 12(4):411-8 (2001).
[cited by applicant]
Le Gall, F. et al., Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody, Protein Eng. Des. Sel., 17(4):357-66 (2004).
[cited by applicant]
Lee, E.C. et al., Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery, Nat. Biotechnol., 32(4):356-63 (2014).
[cited by applicant]
Lee, H. et al., Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies, Nat. Biotechnol., 24(10):1279-1284 (2006).
[cited by applicant]
Lefranc, M.P. and Lefranc, G., Immunoglobulin Facts Book, London: Academic Press, pp. 3-44, 98-100, and 102 (2001).
[cited by applicant]
Lefranc, M.P. Nomenclature of the human immunoglobulin heavy (IGH) genes, Exp. Clin. Immunogenet., 18(2):100-16 (2001).
[cited by applicant]
Lefranc, M.P., Nomenclature of the Human Immunoglobulin Genes Current Protocols in Immunology, Supplement 40:A.1P.1-A.1P.37 (2000).
[cited by applicant]
Lefranc, M.P., Nomenclature of the human immunoglobulin kappa (IGK) genes, Exp. Clin. Immunogenet., 18(3):161-74 (2001).
[cited by applicant]
Lefranc, M-P. and Lefranc, G., The Immunoblobulin Facts Books, San Diego, CA: Academic Press, entire book, pp. 1-457 (2001).
[cited by applicant]
Leitzgen, K. et al., Assembly of immunoglobulin Light Chains as a Prerequisite for Secretion, Journal of Biological Chemistry, 272(5):3117-3123 (1997).
[cited by applicant]
Letter Accompanying Initial Post-Hearing Submissions (Applicant) for Australian patent application No. 2009263082, 1 page (Oct. 5, 2016).
[cited by applicant]
Letter in Reply to Merus Response in EP2147594, 9 pages (Aug. 20, 2015).
[cited by applicant]
Liao, M.J. and Van Dyke, T., Critical role for Atm in suppressing V(D)J recombination-driven thymic lymphoma, Genes Dev., 13(10):1246-50 (1999).
[cited by applicant]
Lindhofer, H. et al., Preferential Species-Restricted Heavy/Light Chain Pairing in Rat/Mouse Quadromas, The Journal of Immunology, 155:219-225 (1995).
[cited by applicant]
Logtenberg, T., Antibody cocktails: next-generation biopharmaceuticals with improved potency, Trends Biotechnol., 25(9):390-4 (2007).
[cited by applicant]
Lonberg, N. et al., Antigen-specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications, Nature, 368:856-859, (1994).
[cited by applicant]
Lonberg, N., Fully human antibodies from transgenic mouse and phage display platforms, Curr. Opin. Immunol., 20(4):450-9, and supplemental material, 16 pages (2008).
[cited by applicant]
Lonberg, N., Human antibodies from transgenic animals, Nature Biotechnology, 23(9):1117-1125 (2005).
[cited by applicant]
Lonberg, N., Human Monoclonal Antibodies from Transgenic Mice, Therapeutic Antibodies, Handbook of Experimental Pharmacology, Eds. Chernajovsky, Y and Nissim, A., Berlin Heidelberg: Springer-Verlag, 181: 69-97 (2008).
[cited by applicant]
Longo, N. et al., Characterization of immunoglobulin gene somatic hypermutation in the absence of activation-induced cytidine deaminase, J. Immunol., 181(2):1299-1306 (2008).
[cited by applicant]
Luby, T.M. et al., The mu Switch Region Tandem Repeats Are Important, but Not Required, for Antibody Class Switch Recombination, J. Exp. Med., 193(2):159-168 (2001).
[cited by applicant]
MacDonald, L. et al., Velocigene Technology Extended to Humanization of Several Megabases of Complex Gene Loci, First International MUGEN Conference of Animal Models for Human Immunological Disease, Sep. 10-13, 2006—Ath…
[cited by applicant]
Manis, J.P. et al., Mechanism and control of class-switch recombination, Trends. Immunol., 23(1):31-9 (2002).
[cited by applicant]
Martinez-Jean, C. et al., Nomenclature and overview of the mouse (
[cited by applicant]
Marvin, J. and Zhu, Z., Recombinant approaches to IgG-like bispecific antibodies, Acta Pharmacologica Sinica, 26(6):649-658 (2005).
[cited by applicant]
Matsuda, F. et al., The Complete Nucleotide Sequence of the Human Immunoglobulin Heavy Chain Variable Region Locus, J. Exp. Med., 188(11): 2151-2162 (1998).
[cited by applicant]
Mendez M.J., et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, Nat Genet. 15(2):146-56 (1997).
[cited by applicant]
Merchant, A. et al., An efficient route to human bispecific IgG, Nature Biotechnology, 16(7):677-681 (1998).
[cited by applicant]
Merus Final Written Submissions as filed in EP2147594 / 09075279.1-1405, 32 pages (Aug. 26, 2016).
[cited by applicant]
Merus Response to REGN Opposition in EP2147594, 35 pages (Apr. 2, 2015).
[cited by applicant]